查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701396

美国子宫肌瘤治疗设备市场规模、份额、趋势分析报告：按技术、治疗模式、细分市场预测，2025-2030 年

U.S. Uterine Fibroids Treatment Devices Market Size, Share & Trends Analysis Report By Technology (Surgical Techniques, Laparoscopic Techniques), By Mode of Treatment (Invasive Treatment, Minimally Invasive Treatment), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

美国子宫肌瘤治疗设备市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，美国子宫肌瘤治疗设备市场规模预计到2030年将达到47.1亿美元，2025年至2030年期间的复合年增长率为9.3%。

由于人们对子宫肌瘤治疗方案的认识不断提高、微创手术的进步以及对子宫切除术替代方案的保留子宫手术的需求不断增加，美国子宫肌瘤治疗设备行业正在经历显着增长。此外，育龄妇女子宫肌瘤盛行率的增加和创新治疗设备的普及是推动市场扩张的主要因素。

子宫肌瘤治疗设备的创新不断改变患者的照护。最近的 FDA核准和产品发布为更有效、更少侵入性的治疗方案铺平了道路。 2024 年 9 月，专门为症状性子宫肌瘤提供微创解决方案的医疗设备公司 Gynesonics Inc. 宣布为其 Sonata 系统发布新的 SMART OS 2.4 软体技术。这种创新治疗方法将第一个也是唯一一个子宫内超音波系统与专有的先进射频消融设备相结合，为治疗有症状的子宫肌瘤提供了一种无切口、保留子宫、经子宫颈的选择。这些进步凸显了该行业致力于改善患者治疗效果同时降低手术风险的承诺。

市场正在转向非手术、保留子宫的治疗方法。子宫切除术等传统外科手术正在被侵入性较小的方法所取代，这些方法可以缩短恢復时间、减少併发症并提高患者的生活品质。子子宫镜肌瘤摘除、腹腔镜肌瘤摘除和非侵入性超音波治疗越来越受到患者和医疗保健提供者的欢迎。

由于技术不断进步、微创手术的保险覆盖范围不断扩大以及人们对女性生殖健康的兴趣日益浓厚，美国子宫肌瘤治疗设备行业有望持续增长。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国子宫肌瘤治疗设备市场变数、趋势与范围

  • 市场展望
    • 附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国子宫肌瘤治疗设备市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国子宫肌瘤治疗设备市场：按技术分類的预测和趋势分析

  • 细分仪表板
  • 美国子宫肌瘤治疗设备市场技术波动分析
  • 美国子宫肌瘤治疗设备市场规模及趋势分析（依技术分类，2018-2030）
  • 手术技术
    • 子宫切除术
    • 子宫肌瘤切除术
  • 腹腔镜手术
    • 腹腔镜子宫肌瘤切除术
    • 肌溶解症
  • 消融技术
    • 微波消融
    • 热液烧蚀
    • 冷冻疗法
    • 超音波消融
  • 栓塞治疗

第五章美国子宫肌瘤治疗设备市场：按治疗模式的估计和趋势分析

  • 细分仪表板
  • 美国子宫肌瘤治疗器材市场依治疗模式波动分析
  • 美国子宫肌瘤治疗器械市场规模及趋势分析（依治疗方式，2018-2030年）
  • 侵入性治疗
  • 微创治疗
  • 非侵入性治疗

第六章竞争格局

  • 市场参与企业分类
  • 主要企业简介
  • Medtronic
  • Stryker
  • Boston Scientific Corporation
  • Insightec.
  • CooperSurgical Inc.
  • Hologic, Inc.
  • CONMED Corporation.
  • Merit Medical Systems.
  • Minerva Surgical, Inc.
Product Code: GVR-4-68040-544-1

U.S. Uterine Fibroids Treatment Devices Market Growth & Trends:

The U.S. uterine fibroids treatment devices market size is anticipated to reach USD 4.71 billion by 2030 and is anticipated to expand at a CAGR of 9.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The U.S. uterine fibroids treatment devices industry is experiencing significant growth due to the rising awareness of fibroid treatment options, advancements in minimally invasive procedures, and increasing demand for uterus-preserving alternatives to hysterectomy. In addition, the growing prevalence of uterine fibroids among women of reproductive age and the availability of innovative treatment devices are key factors driving market expansion.

Innovations in fibroid treatment devices continue to transform patient care. Recent FDA approvals and product launches have concreted the way for more effective and less invasive treatment options. In September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the release of its new SMART OS 2.4 software technology for the Sonata System. This innovative treatment combines the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, offering an incision-free, uterus-preserving, transcervical option for treating symptomatic uterine fibroids. Such advancements highlight the industry's commitment to improving patient outcomes while reducing procedural risks.

The market is shifting toward non-surgical and uterus-sparing treatment approaches. Traditional surgical procedures, such as hysterectomy, are being replaced by less invasive methods that offer reduced recovery time, fewer complications, and improved quality of life for patients. Hysteroscopic myomectomy, laparoscopic myomectomy, and non-invasive ultrasound therapy are gaining traction among patients and healthcare providers.

With ongoing technological advancements, increased insurance coverage for minimally invasive procedures, and a growing focus on women's reproductive health, the U.S. uterine fibroids treatment devices industry is poised for sustained growth.

U.S. Uterine Fibroids Treatment Devices Market Report Segmentation

  • Based on technology, the surgical technologies segment dominates the market with the largest revenue share owing to the increasing prevalence of uterine fibroids among women, necessitating effective surgical interventions.
  • Based on mode of treatment, the invasive treatment segment dominates the market with the largest revenue share owing to the high adoption of hysterectomy and myomectomy procedures, which offer definitive fibroid removal. Advancements in laparoscopic and robotic-assisted surgeries, along with strong insurance coverage, further solidified its market dominance.
  • In January 2025, Hologic, Inc. acquired Gynesonics, Inc., a privately held company specializing in minimally invasive solutions for uterine fibroid treatment, for approximately USD 350 million. Gynesonics is renowned for its Sonata System, an innovative technology that combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation to treat symptomatic uterine fibroids without incisions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Third Party Perspective
    • 1.3.5. Primary research
    • 1.3.6. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Uterine Fibroids Treatment Devices Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of uterine fibroids
      • 3.2.1.2. Advancements in minimally invasive procedures
      • 3.2.1.3. Increasing awareness and early diagnosis
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of advanced treatment devices
  • 3.3. U.S. Uterine Fibroids Treatment Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal Landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape

Chapter 4. U.S. Uterine Fibroids Treatment Devices Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Uterine Fibroids Treatment Devices Market Technology Movement Analysis
  • 4.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 4.4. Surgical Techniques
    • 4.4.1. Surgical Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Hysterectomy
      • 4.4.2.1. Hysterectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Myomectomy
      • 4.4.3.1. Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Laparoscopic Techniques
    • 4.5.1. Laparoscopic Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Laparoscopic Myomectomy
      • 4.5.2.1. Laparoscopic Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Myolysis
      • 4.5.3.1. Myolysis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Ablation Techniques
    • 4.6.1. Ablation Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. Microwave Abalation
      • 4.6.2.1. Microwave Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. Hydrothermal Abalation
      • 4.6.3.1. Hydrothermal Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4. Cyroablation
      • 4.6.4.1. Cyroablation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5. Ultrasound Abalation
      • 4.6.5.1. Ultrasound Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.6.5.2. High Intensity Focused Ultrasound (HIFU)
        • 4.6.5.2.1. High Intensity Focused Ultrasound (HIFU) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.6.5.3. MRI-guided Focused Ultrasound (MRgFUS)
        • 4.6.5.3.1. MRI-guided Focused Ultrasound (MRgFUS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Embolization Techniques
    • 4.7.1. Embolization Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Uterine Fibroids Treatment Devices Market: Mode of Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Uterine Fibroids Treatment Devices Market Mode of Treatment Movement Analysis
  • 5.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Mode of Treatment, 2018 to 2030 (USD Million)
  • 5.4. Invasive Treatment
    • 5.4.1. Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Minimally Invasive Treatment
    • 5.5.1. Minimally Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Non-invasive Treatment
    • 5.6.1. Non-invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
  • 6.2. Key Company Profiles
    • 6.2.1. Medtronic
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Service Benchmarking
      • 6.2.1.4. Strategic Initiatives
  • 6.3. Stryker
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Service Benchmarking
      • 6.3.1.4. Strategic Initiatives
  • 6.4. Boston Scientific Corporation
      • 6.4.1.1. Company Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Service Benchmarking
      • 6.4.1.4. Strategic Initiatives
  • 6.5. Insightec.
      • 6.5.1.1. Company Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Service Benchmarking
      • 6.5.1.4. Strategic Initiatives
  • 6.6. CooperSurgical Inc.
      • 6.6.1.1. Company Overview
      • 6.6.1.2. Financial Performance
      • 6.6.1.3. Service Benchmarking
      • 6.6.1.4. Strategic Initiatives
  • 6.7. Hologic, Inc.
      • 6.7.1.1. Company Overview
      • 6.7.1.2. Financial Performance
      • 6.7.1.3. Service Benchmarking
      • 6.7.1.4. Strategic Initiatives
  • 6.8. CONMED Corporation.
      • 6.8.1.1. Company Overview
      • 6.8.1.2. Financial Performance
      • 6.8.1.3. Service Benchmarking
      • 6.8.1.4. Strategic Initiatives
  • 6.9. Merit Medical Systems.
      • 6.9.1.1. Company Overview
      • 6.9.1.2. Financial Performance
      • 6.9.1.3. Service Benchmarking
      • 6.9.1.4. Strategic Initiatives
  • 6.10. Minerva Surgical, Inc.
      • 6.10.1.1. Company Overview
      • 6.10.1.2. Financial Performance
      • 6.10.1.3. Service Benchmarking
      • 6.10.1.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviation
  • Table 3. U.S. Uterine Fibroids Treatment Devices Market, By Technology, 2018 - 2030 (USD Million)
  • Table 4. U.S. Uterine Fibroids Treatment Devices Market, By Mode of Treatment, 2018 - 2030 (USD Million)
  • Table 5. Participant's Overview
  • Table 6. Financial Performance
  • Table 7. Product Benchmarking
  • Table 8. Strategic Initiatives

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 U.S. Uterine Fibroids Treatment Devices Market, Market Segmentation
  • Fig. 7 Market Driver Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Analysis (Current & Future Impact)
  • Fig. 9 Market Opportunity Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 U.S. Uterine Fibroids Treatment Devices Market, for Surgical Techniques, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Uterine Fibroids Treatment Devices Market, for Hysterectomy, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Uterine Fibroids Treatment Devices Market, for Myomectomy, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Uterine Fibroids Treatment Devices Market, for Laparoscopic Techniques, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Uterine Fibroids Treatment Devices Market, for Laparoscopic Myomectomy, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Uterine Fibroids Treatment Devices Market, for Myolysis, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Uterine Fibroids Treatment Devices Market, for Ablation Techniques, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Uterine Fibroids Treatment Devices Market, for Microwave Ablation, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Uterine Fibroids Treatment Devices Market, for Hydrothermal Ablation, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Uterine Fibroids Treatment Devices Market, for Cryoablation, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Uterine Fibroids Treatment Devices Market, for Ultrasound Ablation, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Uterine Fibroids Treatment Devices Market, for High Intensity Focused Ultrasound (HIFU), 2018 - 2030 (USD Million)
  • Fig. 26 U.S. Uterine Fibroids Treatment Devices Market, for MRI-guided Focused Ultrasound (MRgFUS), 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Uterine Fibroids Treatment Devices Market, for Embolization Techniques, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Uterine Fibroids Treatment Devices Market, for Invasive Treatment, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Uterine Fibroids Treatment Devices Market, for Minimally Invasive Treatment, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Uterine Fibroids Treatment Devices Market, for Non-invasive Treatment, 2018 - 2030 (USD Million)